Prisys Biotech, specializing in Non-Human Primate (NHP) models, has recently expanded its translational research platforms to better support drug development in dermatology, neuroscience, pain, and metabolic diseases. The latest capabilities include AI-driven behavioral quantification, iMRI-guided brain delivery for CNS agents, and access to rare NHP cohorts with spontaneous disease phenotypes.
These updates are designed to address persistent gaps in translational relevance that often hinder progression from preclinical studies to successful clinical outcomes.
"Animal models that fail to reflect human disease biology remain a major barrier to therapeutic innovation," said James, General Manager of Prisys Biotech. "Our 2025 mid-year expansion focuses on closing this gap by combining advanced delivery technologies, objective functional endpoints, and disease-relevant NHP models. We aim to support our partners in generating high-quality data that enables confident go/no-go decisions."
Platform Highlights
Dermatology (Atopic Dermatitis & Itch): Toward Objective, Continuous Readouts
Prisys has developed a systemic NHP model of atopic dermatitis (AD) that mirrors key features of the human disease, including barrier dysfunction and common comorbidities such as asthma and allergic rhinitis. To enhance endpoint reliability, Prisys deploys its proprietary BehaviorAtlas® system-an AI-powered 3D motion analysis platform that continuously tracks and quantifies scratching behavior, enabling objective evaluation of anti-pruritic therapies.
Neurodegenerative Diseases (Parkinson's): Precision Delivery Meets Pathophysiology
To support CNS-targeted interventions, Prisys integrates iMRI-guided Convection-Enhanced Delivery (CED) technology for real-time monitoring and precise drug administration into deep brain regions. This platform is currently applied to a diversified portfolio of Parkinson's Disease (PD) models, including classical toxin-induced models and ongoing development of α-synuclein-based models that more closely reproduce PD-associated proteinopathies.
Pain (Acute & Chronic): Comprehensive Models with Functional Readouts
Prisys offers a suite of validated pain models spanning acute (e.g., capsaicin, formalin-induced) and chronic neuropathic conditions (e.g., partial sciatic nerve ligation, PSNL). These models incorporate functional endpoints such as Laser Speckle Contrast Imaging (LSCI) and BOLD-fMRI, enhancing sensitivity and reproducibility. Additional models for spinal nerve ligation (SNL) and chemotherapy-induced peripheral neuropathy (CIPN) are nearing validation.
Metabolic and Age-Related Diseases: Access to Naturally Occurring Phenotypes
Prisys provides access to well-characterized NHP populations exhibiting spontaneous disease phenotypes, including obesity, type 2 diabetes, and aging-related conditions. These cohorts offer unparalleled translational relevance for evaluating therapeutics in pathophysiological contexts similar to human patients.
All research activities at Prisys Biotech are conducted under AAALAC International accreditation, ensuring compliance with the highest standards of animal welfare and scientific integrity.
About Prisys Biotech
Prisys Biotechnologies is a preclinical CRO specializing in translational Non-Human Primate (NHP) models and technologies. With full AAALAC accreditation and a dedicated research center in Shanghai, Prisys integrates advanced platforms including iMRI-guided brain delivery, clinical-grade imaging, and AI-driven behavior analysis to support high-quality drug evaluation. The company has developed over 40 NHP disease models across neuroscience, immunology, and metabolism, and collaborates with global partners to accelerate therapeutic innovation.
